Capital Ideas Media publisher Mark Bunting sits down with Rodney Gelineau, the CEO of EastWest Bioscience (TSXV:EAST), which just completed a reverse takeover with Harbour Star Capital.
Rodney explains EAST’s strategy of moving into cannabinoid (CBD) products to complement the 30+ hemp-based products the company already has on the market.
He also gives revenue and profitability projections, and talks about EAST’s recent purchase of Sangster’s, a health store chain that’s been around since the early 1970s.